Drug Name: Zynyz
Indications: To treat metastatic or recurrent locally advanced Merkel cell carcinoma.
Active Ingredient: Retifanlimab-dlwr
Company: Incyte Corporation
Approval Date: 3/22/2023
More Details: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761334s000lbl.pdf